Status:
COMPLETED
Mild To Moderate Erectile Dysfunction Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Impotence
Eligibility:
MALE
18-70 years
Phase:
PHASE4
Brief Summary
Safety/Efficacy of 100-mg Viagra at 8 hours post dose in men with mild to moderate erectile dysfunction
Eligibility Criteria
Inclusion
- Men 18-70 years of age
- Documented clinical diagnosis of erectile dysfunction of at least 3 months duration.
Exclusion
- Subjects with penile implants
- Subjects with a known history of retinitis pigmentosa.
- Subjects, due to the requirement of 100 mg dosage, who are receiving concomitant treatment with the potent CYP3A4 inhibitor ritonavir.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2006
Estimated Enrollment :
355 Patients enrolled
Trial Details
Trial ID
NCT00137072
Start Date
April 1 2005
End Date
February 1 2006
Last Update
February 1 2021
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States
2
Pfizer Investigational Site
Homewood, Alabama, United States
3
Pfizer Investigational Site
Hoover, Alabama, United States
4
Pfizer Investigational Site
Huntsville, Alabama, United States